{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T17:13:49Z","timestamp":1747156429039,"version":"3.40.5"},"reference-count":95,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","bloodreviews.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.blre.2016.04.003","type":"journal-article","created":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T02:07:24Z","timestamp":1462068444000},"page":"349-356","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Ironing out the details of iron overload in myelofibrosis: Lessons from myelodysplastic syndromes"],"prefix":"10.1016","volume":"30","author":[{"given":"Nicole","family":"Carreau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2584-6953","authenticated-orcid":false,"given":"Douglas","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Savona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Kremyanskaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8400-0483","authenticated-orcid":false,"given":"John","family":"Mascarenhas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.blre.2016.04.003_bb0005","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/ajh.23406","article-title":"Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis","volume":"88","author":"Pardanani","year":"2013","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.blre.2016.04.003_bb0010","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1182\/asheducation-2011.1.222","article-title":"Management of myelofibrosis","volume":"2011","author":"Vannucchi","year":"2011","journal-title":"Hematology"},{"issue":"1","key":"10.1016\/j.blre.2016.04.003_bb0015","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mayocp.2011.11.001","article-title":"One thousand patients with primary myelofibrosis: the Mayo Clinic experience","volume":"87","author":"Tefferi","year":"2012","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.1016\/j.blre.2016.04.003_bb0020","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood.V88.3.1013.1013","article-title":"Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system","volume":"88","author":"Dupriez","year":"1996","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.blre.2016.04.003_bb0025","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2016.04.003_bb0030","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2016.04.003_bb0035","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2016.04.003_bb0040","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMct1004810","article-title":"Iron-chelating therapy for transfusional iron overload","volume":"364","author":"Brittenham","year":"2011","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.blre.2016.04.003_bb0045","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1111\/j.1537-2995.2007.01416.x","article-title":"Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review","volume":"47","author":"Delea","year":"2007","journal-title":"Transfusion"},{"key":"10.1016\/j.blre.2016.04.003_bb0050","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1600-0609.2007.00840.x","article-title":"Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade\u00ae, ICL670)","volume":"78","author":"Di Tucci","year":"2007","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2016.04.003_bb0055","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000158631","article-title":"Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis","volume":"120","author":"Messa","year":"2008","journal-title":"Acta Haematol"},{"year":"2015","series-title":"Iron Deficiency and Other Hypoproliferative Anemias. Harrison's Principles of Internal Medicine, 19e","author":"Adamson","key":"10.1016\/j.blre.2016.04.003_bb0060"},{"issue":"10","key":"10.1016\/j.blre.2016.04.003_bb0065","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.leukres.2014.08.007","article-title":"Clinical significance of microcytosis in patients with primary myelofibrosis","volume":"38","author":"Strati","year":"2014","journal-title":"Leuk Res"},{"issue":"2 SPEC. ISS.","key":"10.1016\/j.blre.2016.04.003_bb0070","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.beha.2004.10.003","article-title":"LPI-labile plasma iron in iron overload","volume":"18","author":"Cabantchik","year":"2005","journal-title":"Best Pract Res Clin Haematol"},{"issue":"4","key":"10.1016\/j.blre.2016.04.003_bb0075","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMra1004967","article-title":"Iron overload in human disease","volume":"366","author":"Fleming","year":"2012","journal-title":"NEJM"},{"key":"10.1016\/j.blre.2016.04.003_bb0080","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1600-0609.2007.00842.x","article-title":"Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity\/mortality","volume":"78","author":"Takatoku","year":"2007","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1016\/j.blre.2016.04.003_bb0085","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.beha.2013.09.009","article-title":"When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes?","volume":"26","author":"Steensma","year":"2013","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.blre.2016.04.003_bb0090","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2014.042","article-title":"Iron chelation therapy with deferasirox in the management of iron overload in primary myelofibrosis","volume":"6","author":"Elli","year":"2014","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.blre.2016.04.003_bb0095","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.3892\/ol.2013.1617","article-title":"Transfusion-dependent low-risk myelodysplastic patients receiving deferasirox: long-term follow-up","volume":"6","author":"Improta","year":"2013","journal-title":"Oncol Lett"},{"issue":"7","key":"10.1016\/j.blre.2016.04.003_bb0100","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s00277-013-1703-7","article-title":"Efficacy and safety of deferasirox in myelodysplastic syndromes","volume":"92","author":"Breccia","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2016.04.003_bb0105","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1445-5994.2012.02734.x","article-title":"When should iron chelation therapy be considered in patients with myelodysplasia and other bone marrow failure syndromes with iron overload?","volume":"42","author":"Bird","year":"2012","journal-title":"Intern Med J"},{"key":"10.1016\/j.blre.2016.04.003_bb0110","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1182\/asheducation-2002.1.136","article-title":"Myelodysplastic syndromes","author":"Greenberg","year":"2002","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.blre.2016.04.003_bb0115","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1046\/j.1365-2141.2003.03907.x","article-title":"Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes","author":"Bowen","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2016.04.003_bb0120","article-title":"Management of anemia associated with myelodysplastic syndrome","volume":"vol 42","author":"Hellstr\u00f6m-Lindberg","year":"2005"},{"issue":"5","key":"10.1016\/j.blre.2016.04.003_bb0125","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/cncr.23280","article-title":"Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes","volume":"112","author":"Jabbour","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2016.04.003_bb0130","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1136\/bmjspcare-2014-000726","article-title":"Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy","volume":"6","author":"Efficace","year":"2016","journal-title":"BMJ Support Palliat Care"},{"issue":"30","key":"10.1016\/j.blre.2016.04.003_bb0135","doi-asserted-by":"crossref","first-page":"7594","DOI":"10.1200\/JCO.2005.01.7038","article-title":"Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making","volume":"23","author":"Malcovati","year":"2005","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.blre.2016.04.003_bb0140","first-page":"1588","article-title":"Predicting survival and leukemic evolution in patients with myelodysplastic syndrome","volume":"91","author":"Malcovati","year":"2006","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.blre.2016.04.003_bb0145","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1002\/cncr.24984","article-title":"Cause of death in patients with lower-risk myelodysplastic syndrome","volume":"116","author":"Dayyani","year":"2010","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.blre.2016.04.003_bb0150","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1099\/jmm.0.46386-0","article-title":"Natural resistance, iron and infection: a challenge for clinical medicine","volume":"55","author":"Bullen","year":"2006","journal-title":"J Med Microbiol"},{"issue":"5","key":"10.1016\/j.blre.2016.04.003_bb0155","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.leukres.2014.02.003","article-title":"Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes","volume":"38","author":"Delforge","year":"2014","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.blre.2016.04.003_bb0160","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.critrevonc.2014.01.006","article-title":"Iron overload and chelation therapy in myelodysplastic syndromes","volume":"91","author":"Temraz","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"issue":"11","key":"10.1016\/j.blre.2016.04.003_bb0165","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/ajh.21269","article-title":"Consensus statement on iron overload in myelodysplastic syndromes","volume":"83","author":"Bennett","year":"2008","journal-title":"Am J Hematol"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2016.04.003_bb0170","first-page":"18","article-title":"Consensus statement on iron overload in myelodysplastic syndromes","volume":"19","author":"Gattermann","year":"2005","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"10.1016\/j.blre.2016.04.003_bb0175","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3324\/haematol.2010.031831","article-title":"Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS","volume":"96","author":"Elena","year":"2011","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.blre.2016.04.003_bb0180","first-page":"210","article-title":"Advances in the management of myelofibrosis","volume":"19","author":"Komrokji","year":"2012","journal-title":"Cancer Control"},{"issue":"1","key":"10.1016\/j.blre.2016.04.003_bb0185","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/ajh.23642","article-title":"Myelodysplastic syndromes: 2014 update","volume":"89","author":"Garcia-Manero","year":"2014","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.blre.2016.04.003_bb0190","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/ajh.21391","article-title":"Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not","volume":"84","author":"Tefferi","year":"2009","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.blre.2016.04.003_bb0195","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/hon.902","article-title":"Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy","volume":"28","author":"Leitch","year":"2010","journal-title":"Hematol Oncol"},{"issue":"6","key":"10.1016\/j.blre.2016.04.003_bb0200","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/j.1365-2141.2010.08275.x","article-title":"Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence","volume":"150","author":"Passamonti","year":"2010","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.blre.2016.04.003_bb0205","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"Suppl. 3","key":"10.1016\/j.blre.2016.04.003_bb0210","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S0145-2126(07)70460-5","article-title":"Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy","volume":"31","author":"Leitch","year":"2007","journal-title":"Leuk Res"},{"issue":"17","key":"10.1016\/j.blre.2016.04.003_bb0215","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1200\/JCO.2010.34.1222","article-title":"Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome","volume":"30","author":"List","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.blre.2016.04.003_bb0220","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3324\/haematol.2009.014696","article-title":"Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias","volume":"95","author":"Cappellini","year":"2010","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.blre.2016.04.003_bb0225","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1600-0609.2007.00842.x","article-title":"Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity\/mortality","volume":"78","author":"Takatoku","year":"2007","journal-title":"Eur J Haematol"},{"issue":"17","key":"10.1016\/j.blre.2016.04.003_bb0230","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1200\/JCO.2009.25.2395","article-title":"Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries","volume":"28","author":"Goldberg","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.blre.2016.04.003_bb0235","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1148\/rg.296095511","article-title":"MR imaging findings of iron overload","volume":"29","author":"Queiroz-Andrade","year":"2009","journal-title":"Radiographics"},{"issue":"9","key":"10.1016\/j.blre.2016.04.003_bb0240","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.3324\/haematol.12759","article-title":"Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias","volume":"93","author":"Di Tucci","year":"2008","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.blre.2016.04.003_bb0245","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1016\/j.transproceed.2007.09.027","article-title":"A magnetic resonance imaging study of iron overload in hemopoietic stem cell transplant recipients with increased ferritin levels","volume":"39","author":"Au","year":"2007","journal-title":"Transplant Proc"},{"issue":"2","key":"10.1016\/j.blre.2016.04.003_bb0250","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1600-0609.2007.00985.x","article-title":"Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study","volume":"80","author":"Porter","year":"2008","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.blre.2016.04.003_bb0255","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1185\/03007990802565867","article-title":"Retrospective study of the association between transfusion frequency and potential complications of iron overload in patients with myelodysplastic syndrome and other acquired hematopoietic disorders","volume":"25","author":"Delea","year":"2009","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"10.1016\/j.blre.2016.04.003_bb0260","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1365-2141.1990.tb07851.x","article-title":"Deferoxamine-induced restoration of haematopoiesis in myelofibrosis secondary to myelodysplasia","volume":"76","author":"Marsh","year":"1990","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.blre.2016.04.003_bb0265","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/(SICI)1096-8652(199603)51:3<243::AID-AJH12>3.0.CO;2-H","article-title":"Improvement of erythropoiesis during treatment with deferiprone in a patient with myelofibrosis and transfusional hemosiderosis [1]","volume":"51","author":"Smeets","year":"1996","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.blre.2016.04.003_bb0270","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000349939","article-title":"Loss of transfusion dependency following deferasirox treatment of iron overload in a woman with myelofibrosis and spherocytosis\u2014a case report","volume":"36","author":"Tesch","year":"2013","journal-title":"Onkologie"},{"issue":"10","key":"10.1016\/j.blre.2016.04.003_bb0275","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1182\/blood-2006-10-054924","article-title":"Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation","volume":"109","author":"Armand","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2016.04.003_bb0280","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.transci.2013.07.004","article-title":"The oral iron chelator deferasirox might improve survival in allogeneic hematopoietic cell transplant (alloHSCT) recipients with transfusional iron overload","volume":"49","author":"Sivgin","year":"2013","journal-title":"Transfus Apher Sci"},{"issue":"3","key":"10.1016\/j.blre.2016.04.003_bb0285","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3324\/haematol.2009.011429","article-title":"Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study","volume":"95","author":"Alessandrino","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2016.04.003_bb0290","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/ajh.22104","article-title":"Iron overload and iron chelation therapy in patients with myelodysplastic syndrome treated by allogeneic stem-cell transplantation: report from the working conference on iron chelation of the Gruppo Italiano Trapianto di Midollo Osseo","volume":"86","author":"Alessandrino","year":"2011","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.blre.2016.04.003_bb0295","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0891-5849(96)00497-2","article-title":"Nontransferrin-bound iron in serum of patients receiving bone marrow transplants","volume":"22","author":"D\u00fcrken","year":"1997","journal-title":"Free Radic Biol Med"},{"issue":"3","key":"10.1016\/j.blre.2016.04.003_bb0300","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1046\/j.1365-2141.2001.02820.x","article-title":"Non-transferrin-bound iron during allogeneic stem cell transplantation","volume":"113","author":"Sahlstedt","year":"2001","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.blre.2016.04.003_bb0305","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00277-007-0266-x","article-title":"Early clinical impact of iron overload in stem cell transplantation. A prospective study","volume":"86","author":"Altes","year":"2007","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.blre.2016.04.003_bb0310","doi-asserted-by":"crossref","first-page":"183","DOI":"10.4149\/neo_2012_024","article-title":"Pretransplant serum ferritin level may be a predictive marker for outcomes in patients having undergone allogeneic hematopoietic stem cell transplantation","volume":"59","author":"Sivgin","year":"2012","journal-title":"Neoplasma"},{"issue":"5","key":"10.1016\/j.blre.2016.04.003_bb0315","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/j.transproceed.2009.11.049","article-title":"Iron overload: predictor of adverse outcome in hematopoietic stem cell transplantation","volume":"42","author":"Sucak","year":"2010","journal-title":"Transplant Proc"},{"key":"10.1016\/j.blre.2016.04.003_bb0320","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1124\/mol.51.5.842","article-title":"Chelation and mobilization of cellular iron by different classes of chelators","volume":"51","author":"Zanninelli","year":"1997","journal-title":"Mol Pharmacol"},{"issue":"4","key":"10.1016\/j.blre.2016.04.003_bb0325","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0022-3476(78)80317-5","article-title":"Excretion of iron in response to deferoxamine in sickle cell anemia","volume":"92","author":"Cohen","year":"1978","journal-title":"J Pediatr"},{"issue":"11","key":"10.1016\/j.blre.2016.04.003_bb0330","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1590\/S0100-879X2002001100009","article-title":"Urinary iron excretion induced by intravenous infusion of deferoxamine in beta-thalassemia homozygous patients","volume":"35","author":"Boturao-Neto","year":"2002","journal-title":"Braz J Med Biol Res"},{"issue":"4","key":"10.1016\/j.blre.2016.04.003_bb0335","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.V95.4.1229.004k32_1229_1236","article-title":"Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia","volume":"95","author":"Davis","year":"2000","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.blre.2016.04.003_bb0340","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1056\/NEJM198604033141402","article-title":"Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions","volume":"314","author":"Olivieri","year":"1986","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.blre.2016.04.003_bb0345","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1097\/01.mph.0000194019.95096.b6","article-title":"Auditory and visual toxicity during deferoxamine therapy in transfusion-dependent patients","volume":"27","author":"Chen","year":"2005","journal-title":"J Pediatr Hematol Off J Am Soc Pediatr Hematol"},{"issue":"3","key":"10.1016\/j.blre.2016.04.003_bb0350","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1365-2141.2006.06455.x","article-title":"A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease","volume":"136","author":"Vichinsky","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2016.04.003_bb0355","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.freeradbiomed.2014.10.513","article-title":"Inhibition of Fe2 +- and Fe3 +-induced hydroxyl radical production by the iron-chelating drug deferiprone","volume":"78","author":"Timoshnikov","year":"2015","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"10.1016\/j.blre.2016.04.003_bb0360","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/11536630-000000000-00000","article-title":"Pharmacokinetics of deferiprone in patients with \u03b2-thalassaemia: impact of splenectomy and iron status","volume":"50","author":"Limenta","year":"2011","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"10.1016\/j.blre.2016.04.003_bb0365","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2165\/00002018-200326080-00003","article-title":"Benefits and risks of deferiprone in iron overload in thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine","volume":"26","author":"Kontoghiorghes","year":"2003","journal-title":"Drug Saf"},{"issue":"1","key":"10.1016\/j.blre.2016.04.003_bb0370","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2002-06-1867","article-title":"Role of deferiprone in chelation therapy for transfusional iron overload","volume":"102","author":"Hoffbrand","year":"2003","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2016.04.003_bb0375","first-page":"795","article-title":"Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective","volume":"3","author":"Galanello","year":"2007","journal-title":"Ther Clin Risk Manag"},{"issue":"5","key":"10.1016\/j.blre.2016.04.003_bb0380","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1182\/blood-2002-10-3280","article-title":"Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone","volume":"102","author":"Cohen","year":"2003","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2016.04.003_bb0385","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1365-2141.1995.tb05274.x","article-title":"Results of long-term deferiprone (L1) therapy: a report by the international study group on oral iron chelators","volume":"91","author":"al-Refaie","year":"1995","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.blre.2016.04.003_bb0390","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1046\/j.1365-2141.2002.03554.x","article-title":"The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients","volume":"118","author":"Ceci","year":"2002","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.blre.2016.04.003_bb0395","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/bjh.13381","article-title":"The iron chelator deferasirox affects redox signalling in haematopoietic stem\/progenitor cells","volume":"170","author":"Tataranni","year":"2015","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.blre.2016.04.003_bb0400","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1124\/dmd.108.022962","article-title":"Pharmacokinetics, distribution, metabolism, and excretion of deferasirox and its iron complex in rats","volume":"36","author":"Bruin","year":"2008","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.blre.2016.04.003_bb0405","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1124\/dmd.109.030833","article-title":"Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state","volume":"38","author":"Waldmeier","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.blre.2016.04.003_bb0410","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1111\/trf.12507","article-title":"Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia","volume":"54","author":"Cheong","year":"2014","journal-title":"Transfusion"},{"issue":"9","key":"10.1016\/j.blre.2016.04.003_bb0415","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.leukres.2010.03.009","article-title":"Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study","volume":"34","author":"Gattermann","year":"2010","journal-title":"Leuk Res"},{"issue":"2","key":"10.1016\/j.blre.2016.04.003_bb0420","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00277-012-1594-z","article-title":"Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload","volume":"92","author":"Nolte","year":"2013","journal-title":"Ann Hematol"},{"issue":"8","key":"10.1016\/j.blre.2016.04.003_bb0425","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/01.COT.0000461150.59619.a2","article-title":"FDA approves new oral formulation of deferasirox, Jadenu, for chronic iron overload","volume":"37","author":"DiGiulio","year":"2015","journal-title":"Oncol Times"},{"key":"10.1016\/j.blre.2016.04.003_bb0430","unstructured":"Jadenu, FDA label. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/206910s000lbl.pdf."},{"issue":"26","key":"10.1016\/j.blre.2016.04.003_bb0435","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.2174\/092986712803251511","article-title":"Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib","volume":"19","author":"Mascarenhas","year":"2012","journal-title":"Curr Med Chem"},{"issue":"9","key":"10.1016\/j.blre.2016.04.003_bb0440","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.blre.2016.04.003_bb0445","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/leu.2013.71","article-title":"Safety and efficacy of CYT387 a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"27","author":"Pardanani","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2016.04.003_bb0450","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.18_suppl.lba7006","article-title":"Results of the PERSIST-1 phase III study of pacritinib (PAC) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia-myelofibrosis (PET-MF)","volume":"33","author":"Mesa","year":"2015","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.blre.2016.04.003_bb0455","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1073\/pnas.0900453106","article-title":"Hepcidin-induced internalization of ferroportin requires binding and cooperative interaction with Jak2","volume":"106","author":"De Domenico","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.blre.2016.04.003_bb0460","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.cmet.2012.03.017","article-title":"Molecular mechanism of hepcidin-mediated ferroportin internalization requires ferroportin lysines, not tyrosines or JAK\u2013STAT","volume":"15","author":"Ross","year":"2012","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/j.blre.2016.04.003_bb0465","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1182\/blood-2006-07-033969","article-title":"STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation","volume":"109","author":"Verga Falzacappa","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.04.003_bb0470","series-title":"EHA Learning Center","article-title":"JAK-inhibitors could induce hepcidin downregulation in patients with myelofibrosis","author":"Del Orbe","year":"2015"},{"key":"10.1016\/j.blre.2016.04.003_bb0475","series-title":"ASH 57th Annu Meet Expo Oral Abstr","article-title":"538. The Jak1\/Jak2 inhibitor momelotinib inhibits Alk2, decreases hepcidin production and ameliorates anemia of chronic disease (ACD) in rodents","author":"Asshoff","year":"2015"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X1630011X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X1630011X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T04:24:11Z","timestamp":1718511851000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X1630011X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":95,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S0268960X1630011X"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2016.04.003","relation":{},"ISSN":["0268-960X"],"issn-type":[{"type":"print","value":"0268-960X"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ironing out the details of iron overload in myelofibrosis: Lessons from myelodysplastic syndromes","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2016.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}